{"protocolSection":{"identificationModule":{"nctId":"NCT00985166","orgStudyIdInfo":{"id":"V221-014"},"secondaryIdInfos":[{"id":"2009_668"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)","officialTitle":"Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age"},"statusModule":{"statusVerifiedDate":"2015-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2000-08"},"primaryCompletionDateStruct":{"date":"2002-05","type":"ACTUAL"},"completionDateStruct":{"date":"2003-05","type":"ACTUAL"},"studyFirstSubmitDate":"2009-09-24","studyFirstSubmitQcDate":"2009-09-25","studyFirstPostDateStruct":{"date":"2009-09-28","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-12-23","resultsFirstSubmitQcDate":"2009-12-23","resultsFirstPostDateStruct":{"date":"2010-01-29","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-07-16","lastUpdatePostDateStruct":{"date":"2015-07-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax."},"conditionsModule":{"conditions":["Measles","Mumps","Rubella","Varicella"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":801,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"ProQuad + Placebo","interventionNames":["Biological: ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)","Biological: Comparator: Placebo"]},{"label":"2","type":"ACTIVE_COMPARATOR","description":"M-M-R II + Placebo","interventionNames":["Biological: Comparator: M-M-R II","Biological: Comparator: Placebo"]},{"label":"3","type":"ACTIVE_COMPARATOR","description":"M-M-R II + Varivax","interventionNames":["Biological: Comparator: M-M-R II","Biological: Comparator: Varivax"]}],"interventions":[{"type":"BIOLOGICAL","name":"ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)","description":"A Single 0.5 mL subcutaneous injection at Day 1","armGroupLabels":["1"],"otherNames":["ProQuad"]},{"type":"BIOLOGICAL","name":"Comparator: M-M-R II","description":"A Single 0.5 mL subcutaneous injection at Day 1","armGroupLabels":["2","3"]},{"type":"BIOLOGICAL","name":"Comparator: Varivax","description":"A Single 0.5 mL subcutaneous injection at Day 1","armGroupLabels":["3"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo","description":"A Single 0.5 mL subcutaneous placebo injection at Day 1","armGroupLabels":["1","2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Antibody Response to Varicella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Varicella","timeFrame":"6 weeks Postvaccination"},{"measure":"Antibody Response to Measles for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Measles","timeFrame":"6 weeks Postvaccination"},{"measure":"Antibody Response to Mumps for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Mumps","timeFrame":"6 weeks Postvaccination"},{"measure":"Antibody Response to Rubella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Rubella","timeFrame":"6 weeks Postvaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In good health\n* Received primary dose of M-M-R II at less than or equal to 12 months of age\n* Received primary dose of Varivax at less than or equal to 12 months of age\n* Negative history of varicella, zoster, measles, mumps, and rubella\n\nExclusion Criteria:\n\n* history of receiving more than once dose of M-M-R II or Varivax\n* Any immune impairment or deficiency\n* Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination\n* Vaccination with an inactive vaccine with in the past 14 days\n* Vaccination with a live vaccine within the past 30 days\n* Receipt of immune globulin, or blood product in the past 5 months","healthyVolunteers":true,"sex":"ALL","minimumAge":"4 Years","maximumAge":"6 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"16452343","type":"RESULT","citation":"Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schodel F, Gress JO, Kuter BJ; Protocol 014 Study Group for ProQuad. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics. 2006 Feb;117(2):265-72. doi: 10.1542/peds.2005-0092."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Prior to entering study, all subjects received primary dose of M-M-R II™ and Varivax™ at less than or equal to 12 months of age.","recruitmentDetails":"17 clinical sites in the United States\n\nDate of first participant visit: 24-Aug-2000\n\nDate of last participant visit: 06-May-2002","groups":[{"id":"FG000","title":"ProQuad™ + Placebo","description":"ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"FG001","title":"M-M-R™ II + Placebo","description":"M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"FG002","title":"M-M-R™ II + VARIVAX™","description":"VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Two randomized subjects withdrew consent before vaccination: no demographic information available.","numSubjects":"401"},{"groupId":"FG001","numSubjects":"205"},{"groupId":"FG002","numSubjects":"195"}]},{"type":"Vaccinated at Visit 1","achievements":[{"groupId":"FG000","numSubjects":"399"},{"groupId":"FG001","numSubjects":"205"},{"groupId":"FG002","numSubjects":"195"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"392"},{"groupId":"FG001","numSubjects":"201"},{"groupId":"FG002","numSubjects":"188"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Test not done","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"ProQuad™ + Placebo","description":"ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"BG001","title":"M-M-R™ II + Placebo","description":"M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"BG002","title":"M-M-R™ II + VARIVAX™","description":"VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"399"},{"groupId":"BG001","value":"205"},{"groupId":"BG002","value":"195"},{"groupId":"BG003","value":"799"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.3","spread":"0.5"},{"groupId":"BG001","value":"4.3","spread":"0.5"},{"groupId":"BG002","value":"4.3","spread":"0.5"},{"groupId":"BG003","value":"4.3","spread":"0.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"191"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"77"},{"groupId":"BG003","value":"373"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"208"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"118"},{"groupId":"BG003","value":"426"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"African American","categories":[{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"93"}]}]},{"title":"Asian/Pacific","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"16"}]}]},{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"313"},{"groupId":"BG001","value":"162"},{"groupId":"BG002","value":"153"},{"groupId":"BG003","value":"628"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"32"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"30"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Antibody Response to Varicella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Varicella","populationDescription":"Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"gpELISA units/mL","timeFrame":"6 weeks Postvaccination","groups":[{"id":"OG000","title":"ProQuad™ + Placebo","description":"ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"OG001","title":"M-M-R™ II + VARIVAX™","description":"VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"171"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"322.2","lowerLimit":"278.9","upperLimit":"372.2"},{"groupId":"OG001","value":"209.3","lowerLimit":"171.2","upperLimit":"255.9"}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Measles for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Measles","populationDescription":"Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mIU/mL","timeFrame":"6 weeks Postvaccination","groups":[{"id":"OG000","title":"ProQuad™ + Placebo","description":"ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"OG001","title":"M-M-R™ II + Placebo","description":"M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"OG002","title":"M-M-R™ II + VARIVAX™","description":"VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"185"},{"groupId":"OG002","value":"171"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1985.9","lowerLimit":"1817.6","upperLimit":"2169.9"},{"groupId":"OG001","value":"2046.9","lowerLimit":"1815.2","upperLimit":"2308.2"},{"groupId":"OG002","value":"2084.3","lowerLimit":"1852.3","upperLimit":"2345.5"}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Mumps for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Mumps","populationDescription":"Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ELISA AB units/mL","timeFrame":"6 weeks Postvaccination","groups":[{"id":"OG000","title":"ProQuad™ + Placebo","description":"ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"OG001","title":"M-M-R™ II + Placebo","description":"M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"OG002","title":"M-M-R™ II + VARIVAX™","description":"VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"185"},{"groupId":"OG002","value":"171"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"206.0","lowerLimit":"188.2","upperLimit":"225.4"},{"groupId":"OG001","value":"308.5","lowerLimit":"269.6","upperLimit":"352.9"},{"groupId":"OG002","value":"295.9","lowerLimit":"262.5","upperLimit":"333.5"}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Rubella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer","description":"Postvaccination observed Geometric Mean Titer of antibody to Rubella","populationDescription":"Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, received M-M-R™ II + VARIVAX™ prior to entering the study, and followed protocol procedures.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"IU/mL","timeFrame":"6 weeks Postvaccination","groups":[{"id":"OG000","title":"ProQuad™ + Placebo","description":"ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"OG001","title":"M-M-R™ II + Placebo","description":"M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1."},{"id":"OG002","title":"M-M-R™ II + VARIVAX™","description":"VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"185"},{"groupId":"OG002","value":"171"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"217.3","lowerLimit":"200.1","upperLimit":"236.0"},{"groupId":"OG001","value":"174.0","lowerLimit":"157.3","upperLimit":"192.6"},{"groupId":"OG002","value":"154.1","lowerLimit":"138.9","upperLimit":"170.9"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","description":"The number of participants listed as \"at risk\" is the number of participants with follow-up.\n\n0/0 indicates that subjects in this treatment group did not receive the indicated vaccine.","eventGroups":[{"id":"EG000","title":"ProQuad™ + Placebo","description":"ProQuad™ (measles, mumps, rubella, and varicella vaccine) + placebo administered concomitantly at separate injection sites on Day 1.","seriousNumAffected":1,"seriousNumAtRisk":397,"otherNumAffected":292,"otherNumAtRisk":397},{"id":"EG001","title":"M-M-R™ II + Placebo","description":"M-M-R™ II + placebo administered concomitantly at separate injection sites on Day 1.","seriousNumAffected":0,"seriousNumAtRisk":205,"otherNumAffected":150,"otherNumAtRisk":205},{"id":"EG002","title":"M-M-R™ II + VARIVAX™","description":"VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 1.","seriousNumAffected":0,"seriousNumAtRisk":193,"otherNumAffected":140,"otherNumAtRisk":193}],"seriousEvents":[{"term":"Pyelonephritis - Not other wise Specified (NOS)","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":0,"numAtRisk":193}]}],"otherEvents":[{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":397},{"groupId":"EG001","numAffected":1,"numAtRisk":205},{"groupId":"EG002","numAffected":4,"numAtRisk":193}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":397},{"groupId":"EG001","numAffected":2,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Abdominal pain NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":397},{"groupId":"EG001","numAffected":4,"numAtRisk":205},{"groupId":"EG002","numAffected":3,"numAtRisk":193}]},{"term":"Diarrhoea NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":397},{"groupId":"EG001","numAffected":7,"numAtRisk":205},{"groupId":"EG002","numAffected":1,"numAtRisk":193}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":397},{"groupId":"EG001","numAffected":1,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Vomiting NOS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":397},{"groupId":"EG001","numAffected":7,"numAtRisk":205},{"groupId":"EG002","numAffected":8,"numAtRisk":193}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":397},{"groupId":"EG001","numAffected":4,"numAtRisk":205},{"groupId":"EG002","numAffected":0,"numAtRisk":193}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Pain NOS","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":397},{"groupId":"EG001","numAffected":1,"numAtRisk":205},{"groupId":"EG002","numAffected":0,"numAtRisk":193}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":397},{"groupId":"EG001","numAffected":20,"numAtRisk":205},{"groupId":"EG002","numAffected":19,"numAtRisk":193}]},{"term":"Venipuncture site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":397},{"groupId":"EG001","numAffected":2,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Ear infection NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":397},{"groupId":"EG001","numAffected":1,"numAtRisk":205},{"groupId":"EG002","numAffected":3,"numAtRisk":193}]},{"term":"Gastroenteritis viral NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":397},{"groupId":"EG001","numAffected":1,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":397},{"groupId":"EG001","numAffected":26,"numAtRisk":205},{"groupId":"EG002","numAffected":26,"numAtRisk":193}]},{"term":"Otitis media NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":397},{"groupId":"EG001","numAffected":9,"numAtRisk":205},{"groupId":"EG002","numAffected":10,"numAtRisk":193}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":397},{"groupId":"EG001","numAffected":7,"numAtRisk":205},{"groupId":"EG002","numAffected":3,"numAtRisk":193}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":397},{"groupId":"EG001","numAffected":3,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Pneumonia NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":397},{"groupId":"EG001","numAffected":1,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Sinusitis NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":397},{"groupId":"EG001","numAffected":6,"numAtRisk":205},{"groupId":"EG002","numAffected":1,"numAtRisk":193}]},{"term":"Upper respiratory tract infection NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":397},{"groupId":"EG001","numAffected":10,"numAtRisk":205},{"groupId":"EG002","numAffected":9,"numAtRisk":193}]},{"term":"Viral infection NOS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":397},{"groupId":"EG001","numAffected":1,"numAtRisk":205},{"groupId":"EG002","numAffected":4,"numAtRisk":193}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":397},{"groupId":"EG001","numAffected":4,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Excoriation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":397},{"groupId":"EG001","numAffected":1,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Appetite decreased NOS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":1,"numAtRisk":193}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":397},{"groupId":"EG001","numAffected":2,"numAtRisk":205},{"groupId":"EG002","numAffected":1,"numAtRisk":193}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":397},{"groupId":"EG001","numAffected":10,"numAtRisk":205},{"groupId":"EG002","numAffected":12,"numAtRisk":193}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":3,"numAtRisk":193}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":397},{"groupId":"EG001","numAffected":3,"numAtRisk":205},{"groupId":"EG002","numAffected":4,"numAtRisk":193}]},{"term":"Asthma NOS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":397},{"groupId":"EG001","numAffected":1,"numAtRisk":205},{"groupId":"EG002","numAffected":3,"numAtRisk":193}]},{"term":"Bronchospasm NOS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":397},{"groupId":"EG001","numAffected":18,"numAtRisk":205},{"groupId":"EG002","numAffected":21,"numAtRisk":193}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":397},{"groupId":"EG001","numAffected":11,"numAtRisk":205},{"groupId":"EG002","numAffected":4,"numAtRisk":193}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":397},{"groupId":"EG001","numAffected":7,"numAtRisk":205},{"groupId":"EG002","numAffected":8,"numAtRisk":193}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":397},{"groupId":"EG001","numAffected":18,"numAtRisk":205},{"groupId":"EG002","numAffected":7,"numAtRisk":193}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":1,"numAtRisk":193}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":3,"numAtRisk":193}]},{"term":"Heat rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":397},{"groupId":"EG001","numAffected":2,"numAtRisk":205},{"groupId":"EG002","numAffected":3,"numAtRisk":193}]},{"term":"Rash NOS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":397},{"groupId":"EG001","numAffected":6,"numAtRisk":205},{"groupId":"EG002","numAffected":4,"numAtRisk":193}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Injection site bruising (M-M-R II Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":5,"numAtRisk":205},{"groupId":"EG002","numAffected":3,"numAtRisk":193}]},{"term":"Injection site erythema (M-M-R II Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":32,"numAtRisk":205},{"groupId":"EG002","numAffected":28,"numAtRisk":193}]},{"term":"Injection site pain (M-M-R II Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":75,"numAtRisk":205},{"groupId":"EG002","numAffected":68,"numAtRisk":193}]},{"term":"Injection site swelling (M-M-R II Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":21,"numAtRisk":205},{"groupId":"EG002","numAffected":15,"numAtRisk":193}]},{"term":"Injection site bruising (ProQuad Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Injection site erythema (ProQuad Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":98,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Injection site pain (ProQuad Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":163,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Injection site pruritus (ProQuad Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Injection site rash (ProQuad Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Injection site swelling (ProQuad Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":62,"numAtRisk":397},{"groupId":"EG001","numAffected":0,"numAtRisk":0},{"groupId":"EG002","numAffected":0,"numAtRisk":0}]},{"term":"Injection site bruising (Varivax Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":4,"numAtRisk":193}]},{"term":"Injection site erythema (Varivax Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":31,"numAtRisk":193}]},{"term":"Injection site nodule (Varivax Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Injection site pain (Varivax Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":71,"numAtRisk":193}]},{"term":"Injection site pruritus (Varivax Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":2,"numAtRisk":193}]},{"term":"Injection site swelling (Varivax Injection-site)","organSystem":"General disorders","sourceVocabulary":"MedDRA 6.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":0},{"groupId":"EG001","numAffected":0,"numAtRisk":205},{"groupId":"EG002","numAffected":21,"numAtRisk":193}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"GMTs (adjusted for prevaccination titer, study center, and primary vaccination history status) have been reported in the literature. One subject received diluent only at visit 1 and was excluded from all immunogenicity/safety summaries."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D008457","term":"Measles"},{"id":"D009107","term":"Mumps"},{"id":"D012409","term":"Rubella"},{"id":"D002644","term":"Chickenpox"}],"ancestors":[{"id":"D018185","term":"Morbillivirus Infections"},{"id":"D018184","term":"Paramyxoviridae Infections"},{"id":"D018701","term":"Mononegavirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"},{"id":"D019351","term":"Rubulavirus Infections"},{"id":"D010309","term":"Parotitis"},{"id":"D010305","term":"Parotid Diseases"},{"id":"D012466","term":"Salivary Gland Diseases"},{"id":"D009059","term":"Mouth Diseases"},{"id":"D009057","term":"Stomatognathic Diseases"},{"id":"D018355","term":"Rubivirus Infections"},{"id":"D014036","term":"Togaviridae Infections"},{"id":"D000073618","term":"Varicella Zoster Virus Infection"},{"id":"D006566","term":"Herpesviridae Infections"},{"id":"D004266","term":"DNA Virus Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"C050102","term":"measles, mumps, rubella, varicella vaccine"}]}},"hasResults":true}